Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-2-3
pubmed:abstractText
Interactions between the Chk1 inhibitor UCN-01 and the farnesyltransferase inhibitor L744832 were examined in human leukemia cells. Combined exposure of U937 cells to subtoxic concentrations of UCN-01 and L744832 resulted in a dramatic increase in mitochondrial dysfunction, apoptosis, and loss of clonogenicity. Similar interactions were noted in other leukemia cells (HL-60, Raji, Jurkat) and primary acute myeloid leukemia (AML) blasts. Coadministration of L744832 blocked UCN-01-mediated phosphorylation of mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK), leading to down-regulation of phospho-cyclic adenosine monophosphate responsive element-binding protein (phospho-CREB) and -p90(RSK) and activation of p34(cdc2) and stress-activated protein kinase/ERK kinase/c-Jun N-terminal kinase (SEK/JNK). Combined treatment also resulted in pronounced reductions in levels of phospho-Akt, -glycogen synthase kinase-3 (-GSK-3), -p70(S6K), -mammalian target of rapamycin (-mTOR), -forkhead transcription factor (-FKHR), -caspase-9, and -Bad. Ectopic expression of Bcl-2 or Bcl-xL but not dominant-negative caspase-8 blocked UCN-01/L744832-mediated mitochondrial dysfunction and apoptosis but did not prevent activation of p34(cdc2) and JNK or inactivation of MEK/ERK and Akt. Enforced expression of myristoylated Akt but not constitutively active MEK significantly attenuated UCN-01/L744832-induced apoptosis. However, dual transfection with Akt and MEK resulted in further protection from UCN-01/L744832-mediated lethality. Finally, down-regulation of JNK1 by siRNA significantly reduced the lethality of the UCN-01/L744832 regimen. Together, these findings suggest that farnesyltransferase inhibitors interrupt the cytoprotective Akt and MAPK pathways while reciprocally activating SAPK/JNK in leukemia cells exposed to UCN-01 and, in so doing, dramatically increase mitochondria-dependent apoptosis.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/7-hydroxystaurosporine, http://linkedlifedata.com/resource/pubmed/chemical/AKT1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Alkyl and Aryl Transferases, http://linkedlifedata.com/resource/pubmed/chemical/Caspases, http://linkedlifedata.com/resource/pubmed/chemical/Checkpoint kinase 1, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Signal-Regulated MAP..., http://linkedlifedata.com/resource/pubmed/chemical/Farnesyltranstransferase, http://linkedlifedata.com/resource/pubmed/chemical/JNK Mitogen-Activated Protein..., http://linkedlifedata.com/resource/pubmed/chemical/L 744832, http://linkedlifedata.com/resource/pubmed/chemical/MAP Kinase Kinase 4, http://linkedlifedata.com/resource/pubmed/chemical/Methionine, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt, http://linkedlifedata.com/resource/pubmed/chemical/Staurosporine
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1706-16
pubmed:dateRevised
2011-11-2
pubmed:meshHeading
pubmed-meshheading:15494423-Humans, pubmed-meshheading:15494423-Leukemia, Myeloid, pubmed-meshheading:15494423-Methionine, pubmed-meshheading:15494423-Cell Transformation, Neoplastic, pubmed-meshheading:15494423-Enzyme Inhibitors, pubmed-meshheading:15494423-Acute Disease, pubmed-meshheading:15494423-Mitochondria, pubmed-meshheading:15494423-Membrane Potentials, pubmed-meshheading:15494423-Drug Synergism, pubmed-meshheading:15494423-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15494423-Enzyme Activation, pubmed-meshheading:15494423-Dose-Response Relationship, Drug, pubmed-meshheading:15494423-Protein Kinases, pubmed-meshheading:15494423-Protein Kinase Inhibitors, pubmed-meshheading:15494423-Apoptosis, pubmed-meshheading:15494423-Alkyl and Aryl Transferases, pubmed-meshheading:15494423-Protein-Serine-Threonine Kinases, pubmed-meshheading:15494423-Proto-Oncogene Proteins, pubmed-meshheading:15494423-Staurosporine, pubmed-meshheading:15494423-HL-60 Cells, pubmed-meshheading:15494423-Proto-Oncogene Proteins c-akt, pubmed-meshheading:15494423-Farnesyltranstransferase, pubmed-meshheading:15494423-JNK Mitogen-Activated Protein Kinases, pubmed-meshheading:15494423-Caspases, pubmed-meshheading:15494423-Jurkat Cells, pubmed-meshheading:15494423-Extracellular Signal-Regulated MAP Kinases, pubmed-meshheading:15494423-MAP Kinase Kinase 4, pubmed-meshheading:15494423-U937 Cells
More...